The Cancer Letter

HIF-2α inhibitor casdatifan yields 35% response rate in kidney cancer, phase I study finds cancerletter.com/clinical-round…

"The next frontier lies in Level III autonomy, where AI agents may become capable of generating hypotheses, prioritizing experiments, and adapting analytical strategies in real time," writes Enrique Velazquez-Villarreal cancerletter.com/trials-and-tri…

“Initial response rates are important, but durability is what ultimately changes practice,” says Jonathan W. Friedberg, MD, MMSc, editor-in-chief of Journal of Clinical Oncology (@JCO_ASCO) cancerletter.com/sponsored-arti…

CMS proposes end-of-life counseling provision, echoing ACA “death panels” controversy cancerletter.com/cancer-policy/…

“Will you commit to us here today that you will carry out our spending laws as Congress intended through appropriations and reconciliations as they were enacted, or not?" The hearing included a dramatic request by @RosaDeLauro that Vought commit to spend all appropriated funds as intended by Congress.   cancerletter.com/capitol-hill/2…

Zoldonrasib + daraxonrasib show 81% ORR in patients with RAS G12D metastatic pancreatic cancer, phase I/II study finds cancerletter.com/clinical-round…

Mark Ratain: “I am not surprised that peer review failed again, which, unfortunately, is not uncommon with many of our top journals.” Feb. 19, Nature Medicine added a notice that the study was under investigation. June 24, the paper was retracted. cancerletter.com/news-analysis/…

@ARPA_H awards up to $160M to advance personalized curative medicines for rare genetic diseases cancerletter.com/in-brief/20260…

Cancer patients with Medicare Advantage have access to fewer providers than Medicare patients, cross-sectional study finds cancerletter.com/cancer-policy/…

. @EU_Commission grants marketing authorization for Tepkinly + R2 in R/R FL cancerletter.com/drugs-and-targ…

The challenge of making the move from conversational AI to autonomous scientific discovery Advancing from level II to level III AI agents in precision medicine Guest editorial by Enrique Velazquez-Villarreal cancerletter.com/trials-and-tri…

The long life of a clinical trial: How @JCO_ASCO sustains landmark oncology research cancerletter.com/sponsored-arti…

Saving Western Kenya’s pediatric blood cancer patients How flow cytometry is changing the diagnostic landscape cancerletter.com/trials-and-tri…

Ned Sharpless’s portrait unveiled at @FNIH_org ceremony cancerletter.com/in-brief/20260…

FDA halts public release of Complete Response Letters, following citizen petition cancerletter.com/cancer-policy/…

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted. The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m. cancerletter.com/news-analysis/…

OMB’s plan to increase political control of science faces stiff opposition on Capitol Hill cancerletter.com/capitol-hill/2…

"With the benefit of experience, however, it has become clear that a screening strategy centered almost exclusively on colonoscopy is increasingly misaligned with today’s public health realities," writes Paul J. Limburg, MD, MPH. @AbbottNews cancerletter.com/trials-and-tri…

Jenna Scott was 29, seven months pregnant, and suddenly, feeling very sick. One year later, in June 2017, shortly after her son turned one, Scott was diagnosed with stage 4 colon cancer. @AmericanCancer cancerletter.com/clinical/20260…

“Maura began making major impactful contributions while still in training. She totally changed our understanding of the etiology of head and neck cancer and demonstrated that one person can make a difference," says Otis Brawley, MD. @UTMDAnderson cancerletter.com/obituary/20260…